{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:09:16Z","timestamp":1785812956806,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ZonMW","award":["848016010"],"award-info":[{"award-number":["848016010"]}]},{"name":"ZonMW","award":["848016010"],"award-info":[{"award-number":["848016010"]}]},{"name":"ZonMW","award":["848016010"],"award-info":[{"award-number":["848016010"]}]},{"name":"ZonMW","award":["848016010"],"award-info":[{"award-number":["848016010"]}]},{"name":"ZonMW","award":["848016010"],"award-info":[{"award-number":["848016010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>For drugs with a narrow therapeutic window, there is a delicate balance between efficacy and toxicity, thus it is pivotal to administer the right dose from the first administration onwards. Exposure of pemetrexed, a cytotoxic drug used in lung cancer treatment, is dictated by kidney function. To facilitate optimized dosing of pemetrexed, accurate prediction of drug clearance is pivotal. Therefore, the aim of this study was to investigate the performance of the kidney function biomarkers serum creatinine, cystatin C and pro-enkephalin in terms of predicting the elimination of pemetrexed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a population pharmacokinetic analysis using a dataset from two clinical trials containing pharmacokinetic data of pemetrexed and measurements of all three biomarkers. A three-compartment model without covariates was fitted to the data and the obtained individual empirical Bayes estimates for pemetrexed clearance were considered the \u201ctrue\u201d values (Cl<jats:sub>true<\/jats:sub>). Subsequently, the following algorithms were tested as covariates for pemetrexed clearance: the Chronic Kidney Disease Epidemiology Collaboration equation using creatinine (CKD-EPI<jats:sub>CR<\/jats:sub>), cystatin C (CKD-EPI<jats:sub>CYS<\/jats:sub>), a combination of both (CKD-EPI<jats:sub>CR-CYS<\/jats:sub>), pro-enkephalin as an absolute value\u00a0or in a combined algorithm with age and serum creatinine, and lastly, a combination of pro-enkephalin with cystatin C.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The dataset consisted of 66 subjects with paired observations for all three kidney function biomarkers. Inclusion of CKD-EPI<jats:sub>CR-CYS<\/jats:sub> as a covariate on pemetrexed clearance resulted in the best model fit, with the largest decrease in objective function (p\u2009&lt;\u20090.00001) and explaining 35% of the total inter-individual variability in clearance. The predictive performance of the model to containing CKD-EPI<jats:sub>CR-CYS<\/jats:sub> to predict pemetrexed clearance was good with a normalized root mean squared error and mean prediction error of 19.9% and 1.2%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, this study showed that the combined CKD-EPI<jats:sub>CR-CYS<\/jats:sub> performs best in terms predicting pharmacokinetics of pemetrexed. Despite the hypothesized disadvantages, creatinine remains to be a suitable and readily available marker to predict pemetrexed clearance in clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-024-04717-w","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T13:01:50Z","timestamp":1728046910000},"page":"799-806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed"],"prefix":"10.1007","volume":"94","author":[{"given":"N.","family":"de Rouw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Beunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Boosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Derijks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. B.","family":"Hilbrands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pickkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"1","key":"4717_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00408-008-9123-5","volume":"187","author":"V Launay-Vacher","year":"2009","unstructured":"Launay-Vacher V, Etessami R, Janus N, Spano JP, Ray-Coquard I, Oudard S, Gligorov J, Pourrat X, Beuzeboc P, Deray G, Morere JF, Renal Insufficiency Anticancer Medications Study G (2009) Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 187(1):69\u201374. https:\/\/doi.org\/10.1007\/s00408-008-9123-5","journal-title":"Lung"},{"issue":"Suppl 4","key":"4717_CR2","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, VanSchil PE, Hellmann MD, Peters S, Committee EG (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv192\u2013iv237. https:\/\/doi.org\/10.1093\/annonc\/mdy275","journal-title":"Ann Oncol"},{"issue":"11","key":"4717_CR3","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748\u20131756. https:\/\/doi.org\/10.1200\/JCO.1989.7.11.1748","journal-title":"J Clin Oncol"},{"issue":"4","key":"4717_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Chaudhary A, Ghosh A, Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57(4):401\u2013411. https:\/\/doi.org\/10.1007\/s00280-005-0036-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4717_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00972-1","author":"N de Rouw","year":"2021","unstructured":"de Rouw N, Boosman RJ, Huitema ADR, Hilbrands LB, Svensson EM, Derijks HJ, van den Heuvel MM, Burger DM, Ter Heine R (2021) Rethinking the application of pemetrexed for patients with renal impairment: a pharmacokinetic analysis. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-020-00972-1","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"4717_CR6","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/ijc.33721","volume":"149","author":"RJ Boosman","year":"2021","unstructured":"Boosman RJ, Dorlo TPC, de Rouw N, Burgers JA, Dingemans AM, van den Heuvel MM, Hendriks LEL, Biesma B, Aerts JGJV, Croes S, Mathijssen R, Huitema ADR, ter Heine R (2021) Toxicity of pemetrexed during renal impairment explained\u2014implications for safe treatment. Int J Cancer 149(8):1576\u20131584","journal-title":"Int J Cancer"},{"issue":"6","key":"4717_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461\u2013470. https:\/\/doi.org\/10.7326\/0003-4819-130-6-199903160-00002","journal-title":"Ann Intern Med"},{"issue":"9","key":"4717_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612","journal-title":"Ann Intern Med"},{"issue":"1","key":"4717_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, Investigators C-E (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367(1):20\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1114248","journal-title":"N Engl J Med"},{"issue":"2","key":"4717_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","volume":"10","author":"K Fearon","year":"2013","unstructured":"Fearon K, Arends J, Baracos V (2013) Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10(2):90\u201399. https:\/\/doi.org\/10.1038\/nrclinonc.2012.209","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"4717_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000319097","volume":"33","author":"L Bodnar","year":"2010","unstructured":"Bodnar L, Wcislo GB, Smoter M, Gasowska-Bodnar A, Stec R, Synowiec A, Szczylik C (2010) Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. Kidney Blood Press Res 33(5):360\u2013367. https:\/\/doi.org\/10.1159\/000319097","journal-title":"Kidney Blood Press Res"},{"key":"4717_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.plabm.2017.05.005","volume":"8","author":"M Jones","year":"2017","unstructured":"Jones M, Denieffe S, Griffin C, Tinago W, Fitzgibbon MC (2017) Evaluation of cystatin C in malignancy and comparability of estimates of GFR in oncology patients. Pract Lab Med 8:95\u2013104. https:\/\/doi.org\/10.1016\/j.plabm.2017.05.005","journal-title":"Pract Lab Med"},{"issue":"5","key":"4717_CR13","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.3892\/ol.2018.9380","volume":"16","author":"WS Kwon","year":"2018","unstructured":"Kwon WS, Kim TS, Nahm CH, Moon Y, Kim JJ (2018) Aberrant cystatin-C expression in blood from patients with breast cancer is a suitable marker for monitoring tumor burden. Oncol Lett 16(5):5583\u20135590. https:\/\/doi.org\/10.3892\/ol.2018.9380","journal-title":"Oncol Lett"},{"issue":"2","key":"4717_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/clinchem\/46.2.193","volume":"46","author":"B \u0160tabuc","year":"2000","unstructured":"\u0160tabuc B, Vrhovec L, \u0160tabuc-\u0160ilih M, Cizej TE (2000) Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 46(2):193\u2013197. https:\/\/doi.org\/10.1093\/clinchem\/46.2.193","journal-title":"Clin Chem"},{"issue":"8","key":"4717_CR15","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1158\/1078-0432.CCR-04-2086","volume":"11","author":"A Hoppe","year":"2005","unstructured":"Hoppe A, Seronie-Vivien S, Thomas F, Delord JP, Malard L, Canal P, Chatelut E (2005) Serum cystatin C is a better marker of topotecan clearance than serum creatinine. Clin Cancer Res 11(8):3038\u20133044. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2086","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4717_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2165\/00003088-200544120-00009","volume":"44","author":"F Thomas","year":"2005","unstructured":"Thomas F, S\u00e9ronie-Vivien S, Gladieff L, Dalenc F, Durrand V, Malard L, Lafont T, Poublanc M, Bugat R, Chatelut E (2005) Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet 44(12):1305\u20131316. https:\/\/doi.org\/10.2165\/00003088-200544120-00009","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"4717_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1159\/000509352","volume":"144","author":"M Khorashadi","year":"2020","unstructured":"Khorashadi M, Beunders R, Pickkers P, Legrand M (2020) Proenkephalin: a new biomarker for glomerular filtration rate and acute kidney injury. Nephron 144(12):655\u2013661. https:\/\/doi.org\/10.1159\/000509352","journal-title":"Nephron"},{"key":"4717_CR18","first-page":"00539","volume":"23","author":"A Loeser","year":"2024","unstructured":"Loeser A, Kim JS, Peppercorn J, Burkard ME, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C (2024) The right dose: results of a patient advocate-led survey of individuals with metastatic breast cancer regarding treatment-related side effects and views about dosage assessment to optimize quality of life. JCO Oncol Pract OP 23:00539","journal-title":"JCO Oncol Pract OP"},{"key":"4717_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00280-019-04006-x","volume":"85","author":"N de Rouw","year":"2020","unstructured":"de Rouw N, Visser S, Koolen SL, Aerts JG, van den Heuvel MM, Derijks HJ, Burger DM, Ter Heine R (2020) A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions. Cancer Chemother Pharmacol 85:231\u2013235","journal-title":"Cancer Chemother Pharmacol"},{"key":"4717_CR20","unstructured":"IMPROVE-I. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03656549?term=pemetrexed&recrs=a&phase=1&rank=5."},{"key":"4717_CR21","unstructured":"IMPROVE-II. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03655821?term=pemetrexed&recrs=a&age=1&rank=15."},{"issue":"1","key":"4717_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clnu.2018.08.002","volume":"38","author":"T Cederholm","year":"2019","unstructured":"Cederholm T, Jensen GL, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van Gossum A, Compher C (2019) GLIM criteria for the diagnosis of malnutrition\u2014a consensus report from the global clinical nutrition community. Clin Nutr 38(1):1\u20139. https:\/\/doi.org\/10.1016\/j.clnu.2018.08.002","journal-title":"Clin Nutr"},{"key":"4717_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clinbiochem.2018.05.010","volume":"58","author":"LJ Donato","year":"2018","unstructured":"Donato LJ, Meeusen JW, Lieske JC, Bergmann D, Sparwa\u00dfer A, Jaffe AS (2018) Analytical performance of an immunoassay to measure proenkephalin. Clin Biochem 58:72\u201377. https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.05.010","journal-title":"Clin Biochem"},{"issue":"11","key":"4717_CR24","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.ekir.2023.08.006","volume":"8","author":"R Beunders","year":"2023","unstructured":"Beunders R, Donato LJ, van Groenendael R, Arlt B, Carvalho-Wodarz C, Schulte J, Coolen AC, Lieske JC, Meeusen JW, Jaffe AS, Pickkers P (2023) Assessing GFR with proenkephalin. Kidney Int Rep 8(11):2345\u20132355. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.006","journal-title":"Kidney Int Rep"},{"issue":"4","key":"4717_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4):503\u2013512","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"4717_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0169-7439(99)00027-1","volume":"49","author":"NM Faber","year":"1999","unstructured":"Faber NM (1999) Estimating the uncertainty in estimates of root mean square error of prediction: application to determining the size of an adequate test set in multivariate calibration. Chemomertr Intell Lab Syst 49(1):79\u201389. https:\/\/doi.org\/10.1016\/S0169-7439(99)00027-1","journal-title":"Chemomertr Intell Lab Syst"},{"issue":"6","key":"4717_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40620-014-0163-z","volume":"28","author":"R Marino","year":"2015","unstructured":"Marino R, Struck J, Hartmann O, Maisel AS, Rehfeldt M, Magrini L, Melander O, Bergmann A, Di Somma S (2015) Diagnostic and short-term prognostic utility of plasma pro-enkephalin (pro-ENK) for acute kidney injury in patients admitted with sepsis in the emergency department. J Nephrol 28(6):717\u2013724. https:\/\/doi.org\/10.1007\/s40620-014-0163-z","journal-title":"J Nephrol"},{"issue":"2","key":"4717_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2133\/dmpk.DMPK-13-RG-042","volume":"29","author":"T Kurata","year":"2014","unstructured":"Kurata T, Iwamoto T, Kawahara Y, Okuda M (2014) Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3. Drug Metab Pharmacokinet 29(2):148\u2013153","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"4717_CR29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/ki.1991.331","volume":"40","author":"LB Hilbrands","year":"1991","unstructured":"Hilbrands LB, Artz MA, Wetzels JF, Koene RA (1991) Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 40(6):1171\u20131176","journal-title":"Kidney Int"},{"issue":"4","key":"4717_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1158\/1078-0432.CCR-11-2503","volume":"18","author":"G Ciarimboli","year":"2012","unstructured":"Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstadt H, Massmann V, Guckel D, Mathijssen RH, Yang W, Pui CH, Relling MV, Herrmann E, Sparreboom A (2012) Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 18(4):1101\u20131108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2503","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4717_CR31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/SHK.0000000000001510","volume":"54","author":"R Beunders","year":"2020","unstructured":"Beunders R, van Groenendael R, Leijte GP, Kox M, Pickkers P (2020) Proenkephalin compared to conventional methods to assess kidney function in critically ill sepsis patients. Shock 54(3):308\u2013314. https:\/\/doi.org\/10.1097\/SHK.0000000000001510","journal-title":"Shock"},{"issue":"3","key":"4717_CR32","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1124\/jpet.107.123323","volume":"322","author":"S-i Matsumoto","year":"2007","unstructured":"Matsumoto S-i, Yoshida K, Ishiguro N, Maeda T, Tamai I (2007) Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(<em>S<\/em>)-9-dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride]. J Pharmacol Exp Ther 322(3):1246\u20131252. https:\/\/doi.org\/10.1124\/jpet.107.123323","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4717_CR33","first-page":"89","volume":"284","author":"WC Zamboni","year":"1998","unstructured":"Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X, Stewart CF (1998) Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J Pharmacol Exp Ther 284(1):89\u201394","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"4717_CR34","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1158\/1078-0432.Ccr-09-0017","volume":"15","author":"A Schmitt","year":"2009","unstructured":"Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E (2009) A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 15(10):3633\u20133639. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4717_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2515\/therapie:2007019","volume":"62","author":"F Thomas","year":"2007","unstructured":"Thomas F, S\u00e9ronie-Vivien S, Malard L, Chatelut E (2007) Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys. Therapie 62(2):121\u2013127. https:\/\/doi.org\/10.2515\/therapie:2007019","journal-title":"Therapie"},{"issue":"5","key":"4717_CR36","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/cpt.2529","volume":"111","author":"N de Rouw","year":"2022","unstructured":"de Rouw N, de Boer M, Boosman RJ, van den Heuvel MM, Burger DM, Lieverse JE, Derijks HJ, Frederix GW, Ter Heine R (2022) The pharmacoeconomic benefits of pemetrexed dose individualization in patients with lung cancer. Clin Pharmacol Ther 111(5):1103\u20131110","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04717-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04717-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04717-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:25:46Z","timestamp":1732033546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04717-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["4717"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04717-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"20 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NdR, RB, RB, HD, DB, LB, RtH: none. MvdH: Research funding: AstraZeneca, BMS, Janssen, Treatmeds, Merck, MSD, Novartis, Pfizer, Roche, Roche diagnostics Advisory\/Speaker fees: Abbvie, AstraZeneca, BMS, Lilly, MSD, Novartis, Pfizer, Roche\u00a0ther: SON-NVALT, NVALT-studies, Longkankernet. PP: received travel and consultancy reimbursements from Sphingotec.\u00a0OH and JSc are employed by SphingoTec GmbH, the manufacturer of the PENK assay.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}